SCHOTT Pharma and KORU Medical Systems Partner to Offer High-Volume Subcutaneous Drug Infusion Solution
Introduction
SCHOTT Pharma and KORU Medical Systems have formed a partnership to develop a high-volume subcutaneous drug infusion solution that will make it easier and safer for patients and healthcare providers to administer large volume doses of medications.
About SCHOTT Pharma
SCHOTT Pharma is a world-leading provider of drug containment solutions and delivery systems. The company’s portfolio includes prefillable glass and polymer syringes, cartridges, vials, and ampoules that are specifically designed for injectable drugs. With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and a team of over 4,600 people from over 60 nations, SCHOTT Pharma is committed to contributing to global healthcare. The company is represented in all main pharmaceutical hubs, with 16 manufacturing sites in Europe, North and South America, and Asia. SCHOTT Pharma has over 1,800 customers, including the top 30 leading pharma manufacturers for injectable drugs, and generated revenue of EUR 899 million in the fiscal year 2023.
About KORU Medical Systems
KORU Medical Systems is a leading medical technology company that focuses on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions. The company’s FREEDOM Syringe Infusion System includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The Freedom System has been used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional since receiving its first FDA clearance in 1994. KORU Medical also provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories.
The Partnership
By combining KORU Medical’s expertise in pump devices with SCHOTT Pharma’s expertise in large-volume prefillable polymer syringes, the two companies aim to improve the time-to-market of infusion therapies while simplifying the subcutaneous drug infusion of large volume drugs. The high-volume subcutaneous drug infusion solution will particularly address the market for treatments that are administered subcutaneously and require recurring dosing regimens, such as chronic diseases or cancer.
The Solution
KORU Medical’s Freedom System is used in conjunction with SCHOTT Pharma prefillable polymer syringes that come prefilled with the exact drug dosage and are capable of being delivered via the FREEDOM60 and FreedomEdge Syringe Infusion Drivers. The syringes are available in large-volume formats from 5mL to 50mL to meet the need for larger infusion volumes and higher drug viscosities. The combination of these two technologies has already demonstrated their ability to solve the subcutaneous immunoglobulin therapy market leader’s transition from vials to PFS. This de-risks the development pathway for pharmaceutical companies, ensuring a successful transition to large volume administration.
The Benefits
Patients and healthcare professionals will benefit from the high-volume subcutaneous drug infusion solution as there are no vial preparation steps needed, simplifying the process for patients and reducing the risk of administration errors. The partnership will also simplify drug development for pharmaceutical partners, ensuring greater success of large volume administration for patients.
Conclusion
SCHOTT Pharma and KORU Medical Systems’ partnership in developing a high-volume subcutaneous drug infusion solution will make it easier and safer for patients and healthcare providers to administer large volume doses of medications. This solution is particularly relevant for treatments that require recurring dosing regimens and when administering larger infusion volumes. By combining their expertise, the two companies offer a de-risked development pathway to ensure a successful transition to large volume administration for pharmaceutical companies. This partnership shows a commitment to making patient-centered healthcare more widely available.
Read more about this topic at
Investigational Drugs for Chronic Inflammatory …
Principles of Opioid Use in Cancer Pain